Table 3.

Demographic, clinical, and biological parameters depending on Crohn’s disease behaviour*

	B1	B2	B3	p Value
Age at diagnosis (%) (n=163)	n=110	n=18	n=35
<40 years (A1)	82.0	88.9	94.3	0.18
>40 years (A2)	18.0	11.1	5.7
Location of the disease (%) (n=163)	n=110	n=18	n=35
Ileal (L1)	38.2	89.9	45.7	0.0003
Colonic (L2)	33.6	0	22.9
Ileocolonic (L3)	23.6	0	28.6
Upper gastrointestinal tract (L4)	4.6	11.1	2.9
Sex (%) (n=163)	n=110	n=18	n=35
Male	34.5	22.2	37.1	0.53
Female	65.5	77.8	62.9
Smoking habit (%) (n=124)	n=79	n=16	n=29
Yes	41.8	62.5	65.5	0.052
No	58.2	37.5	34.5
Familial disease (%) (n= 156)	n=106	n=16	n=34
Yes	17.0	31.3	5.9	0.07
No	83.0	68.7	94.1
ASCA (%) (n=90)	n=54	n=14	n=22
Positive	64.8	35.7	72.7	0.044
Negative	35.2	64.3	27.3
NOD2/CARD15 (%) (n=101)	n=48	n=18	n=35
Wild-type	47.9	44.4	68.6	0.34
Heterozygotes	39.6	38.9	22.8
Homozygotes and compound heterozygotes	12.5	16.7	8.6
Steroid courses (No/year) (n=126)	n=83	n=15	n=28
	0.35 (0.48)*	0.23 (0.26)*	0.69 (0.71)*	0.026
Flares of CD (No/year) (n=126)	n=83	n=15	n=28
	0.74 (0.77)*	0.68 (0.22)*	1.53 (0.82)*	<0.0001
Azathioprine treatment (months/year) (n=145)	n=99	n=16	n=30
	0.25 (0.12)*	0.4 (0.4)*	0.16 (0.16)*	0.84

*B1, non-stricturing non-penetrating; B2, stricturing; B3, penetrating, according to the Vienna classification, five years after diagnosis.

p values correspond to univariate analysis for each parameter using either χ² or Kruskal Wallis tests, as required.

CD, Crohn’s disease; ASCA, antisaccharomyces cerevisiae antibodies.

*Mean (SD).